Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

    Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

    FromThe Lancet Infectious Diseases in conversation with

    Start listeningView podcast show

    Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

    FromThe Lancet Infectious Diseases in conversation with

    ratings:
    Length:
    14 minutes
    Released:
    Feb 14, 2018
    Format:
    Podcast episode

    Description

    Amir Shroufi discusses the early results assessing the safety and efficacy of the combination of bedaquiline and delamanid against drug-resistant tuberculosis.
    Released:
    Feb 14, 2018
    Format:
    Podcast episode

    Titles in the series (100)

    Our Editors and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.